Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC

Dr. Benjamin Levy introduces an expert panel to discuss the increasingly complex landscape of EGFR-mutant advanced non-small cell lung cancer (NSCLC) treatment. The frontline setting now includes three viable options representing a significant shift from the previously straightforward osimertinib monotherapy approach.

Dr. Ross Camidge outlines the current options: osimertinib monotherapy remains the baseline with median progression-free survival (PFS) of 18 to 19 months. FLAURA-2 adds 4 cycles of carboplatin-pemetrexed with optional pemetrexed maintenance, extending median PFS beyond 2 years. MARIPOSA combines osimertinib with amivantamab, achieving similar PFS approaching 2 years but with distinct toxicity profiles.

Dr. Siddhartha Devarakonda emphasizes that treatment selection has become a philosophical exercise requiring shared decision-making. He notes that approximately 85% of patients have high-risk features warranting intensification, including high disease burden, CNS involvement, TP53 mutations, or elevated circulating tumor DNA levels. However, social factors like language barriers affect treatment feasibility, as 40% of his patients don't speak English, complicating intensive supportive care regimens.

Dr. Gilberto Lopes describes a practice evolution from questioning who needs intensification to identifying who should receive single-agent therapy. Overall survival benefits with intensification are evident across most subgroups, challenging previous assumptions about low-risk patients. The reality that 20% to 30% of patients are lost between first and second-line therapy emphasizes the importance of frontline treatment optimization.